Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27683933 | 1.00 | SMN1; SMN2 (0.33) | SMN1; SMN2ALOX15ALDH1A1NPSR1CYP2C19 | |
| SCHEMBL27683921 | 1.00 | SMN1; SMN2 (0.33) | SMN1; SMN2ALOX15ALDH1A1NPSR1CYP2C19 | |
| SCHEMBL8401641 | 0.97 | ALOX15 (0.33) | SMN1; SMN2ALOX15ALDH1A1NPSR1TSHR | |
| SCHEMBL27664279 | 0.92 | — | — | |
| SCHEMBL6092390 | 0.87 | — | — | |
| SCHEMBL4019607 | 0.79 | CYP2C19 (0.33) | SMN1; SMN2ALDH1A1CYP2C19TSHR | |
| SCHEMBL28787467 | 0.79 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1CYP2C19TSHR | |
| SCHEMBL487008 | 0.78 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4360209 | 0.77 | CYP2C19 (0.34) | SMN1; SMN2ALDH1A1CYP2C19TSHR | |
| SCHEMBL1326935 | 0.77 | ALDH1A1 (0.32) | SMN1; SMN2ALOX15ALDH1A1NPSR1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415572-B | Color material dispersion liquid, colored resin composition, color filter, liquid crystal display device, and light-emitting display device | 大日本印刷株式会社 | 2020-08-28 | — | — | CN | disclosed |
| CN-109415572-A | Color material dispersion liquid, colored resin composition, colour filter, liquid crystal display and light-emitting display apparatus | 大日本印刷株式会社 | 2019-03-01 | — | — | CN | disclosed |
| CN-109020936-A | A kind of preparation method of Spiromesifen and its intermediate | 山东康乔生物科技有限公司 | 2018-12-18 | — | — | CN | disclosed |
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| EP-1471056-B1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-07-11 | — | — | EP | disclosed |
| CN-101490170-A | Curable resin composition and method for forming cured coating film | DAICEL CHEM (JP) | 2009-07-22 | — | — | CN | disclosed |
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-7402698-B2 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1673084-B1 | 1-2' (1,4'-BIPERIDIN-1'-YL)-1-(PHENYL)-ETHYLCYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | WYETH CORP (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1471056-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-6800636-B2 | FOR THERAPY OF CANCER | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6740661-B2 | TRICYCLIC IMINE CONTAINING COMPOUNDS HAVING IMIDAZOLE SUBSTITUENT; ANTITUMOR AGENTS | SCHERING CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | GUZI TIMOTHY (US) | 2003-02-27 | — | — | US | disclosed |
| US-6372747-B1 | ENZYME INHIBITORS AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2002-04-16 | — | — | US | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
| EP-1140902-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140904-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037459-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000037458-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | FNTA, FNTB, CETP | SMN1; SMN2 4730/4885ALOX15 3751/4885ALDH1A1 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.